TCWA
RIGL icon

Ten Capital Wealth Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Ten Capital Wealth Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-200
Closed -$2.64K – 439
2023
Q1 		$2.64K Hold
200
– – ﹤0.01% 451
2022
Q4 		$3K Hold
200
– – ﹤0.01% 419
2022
Q3 		$2K Hold
200
– – ﹤0.01% 489
2022
Q2 		$2K Hold
200
– – ﹤0.01% 400
2022
Q1 		$6K Buy
+200
New +$5.42K ﹤0.01% 355

Other funds holding RIGL

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ten Capital Wealth Advisors's RIGL Position: Q2 2023 in Review

Ten Capital Wealth Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q2 2023, closing a stake of 200 shares — an estimated $2.64K sold.

Ten Capital Wealth Advisors first reported a position in RIGL in Q1 2022 and held it in 5 quarters. The position peaked at $6K in Q1 2022. 118 funds tracked by Wall St. Rank hold RIGL as of Q2 2023.

  • Ten Capital Wealth Advisors reported no remaining Rigel Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Ten Capital Wealth Advisors sold 200 Rigel Pharmaceuticals shares in Q2 2023, an estimated $2.64K.
  • Ten Capital Wealth Advisors first reported a position in Rigel Pharmaceuticals in Q1 2022 and held it in 5 quarters.
  • Ten Capital Wealth Advisors's Rigel Pharmaceuticals position peaked at $6K in Q1 2022.
  • 118 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2023.

Based on Ten Capital Wealth Advisors's 13F filing for Q2 2023, filed 31 Jul 2023.